ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Hopes for new Alzheimer's drug Leqembi lift Eisai shares

Lower cost could help spread use but better testing is key, analysts say

Eisai developed its new Alzheimer's treatment with U.S. partner Biogen. (Photo by Aya Onishi)

TOKYO -- Shares in Japanese drugmaker Eisai rose as much as 9% on Tuesday as investors took in the prospect of an earnings boost from the company's new Alzheimer's drug.

The U.S. Food and Drug Administration approved the drug lecanemab, marketed as Leqembi, under a fast-track program on Friday. The drug was developed with U.S. partner Biogen.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more